Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Current Liabilities: 2022-2024

Historic Total Current Liabilities for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $58.0 million.

  • Centessa Pharmaceuticals' Total Current Liabilities rose 10.29% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.1 million, marking a year-over-year increase of 10.29%. This contributed to the annual value of $58.0 million for FY2024, which is 47.26% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Total Current Liabilities of $58.0 million as of FY2024, which was up 47.26% from $39.4 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Total Current Liabilities ranged from a high of $58.0 million in FY2024 and a low of $38.3 million during FY2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $39.4 million (2023), whereas its average is $45.2 million.
  • Data for Centessa Pharmaceuticals' Total Current Liabilities shows a peak YoY soared of 47.26% (in 2024) over the last 5 years.
  • Over the past 3 years, Centessa Pharmaceuticals' Total Current Liabilities (Yearly) stood at $38.3 million in 2022, then climbed by 2.73% to $39.4 million in 2023, then spiked by 47.26% to $58.0 million in 2024.